TG Therapeutics (TGTX) Stock Price, News & Analysis

Company Overview

TG Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing novel treatments for B-cell cancers and autoimmune diseases. Headquartered in New York, TG Therapeutics focuses on targeted therapies that leverage monoclonal antibodies and small-molecule inhibitors to address critical unmet medical needs. The company’s research and development efforts center on combination approaches designed to improve patient outcomes by attacking disease through complementary mechanisms of action.

The company’s two lead products, ublituximab and umbralisib, have secured regulatory approval for indications in hematologic malignancies. Ublituximab is a glycoengineered anti-CD20 monoclonal antibody, while umbralisib is an oral PI3K delta inhibitor. These agents are marketed for the treatment of relapsed or refractory chronic lymphocytic leukemia, marginal zone lymphoma and follicular lymphoma. Beyond these approved therapies, TG Therapeutics maintains a diversified pipeline, which includes novel compounds such as TG-1701 (a Bruton’s tyrosine kinase inhibitor) and early-stage programs aimed at expanding into multiple sclerosis and other immune-mediated conditions.

Founded in 2007, TG Therapeutics has grown through strategic collaborations and acquisitions. The company has entered into partnerships with academic centers and biotechnology firms to accelerate development and optimize commercial strategies. While its primary market is the United States, TG Therapeutics is pursuing regulatory filings and distribution agreements in Europe, Canada and parts of Asia, laying the groundwork for broader global reach.

Leadership at TG Therapeutics is led by Chairman and Chief Executive Officer Michael S. Weiss, who co-founded the company and has overseen its transition from early-stage research to commercial operations. The executive team brings together expertise in oncology, immunology and specialty pharmaceuticals, supported by a board of directors with deep experience in drug development and market commercialization. Together, they guide TG Therapeutics’ mission to bring innovative therapies to patients suffering from B-cell malignancies and autoimmune disorders.

Key Stats

• Today's Range: $36.07 to $36.96
• 50-Day Range: $33.37 to $45.51
• 52-Week Range: $16.65 to $46.48
• Volume: 681,323 shs
• Average Volume: 2.92 million shs
• Market Capitalization: $5.91 billion
• P/E Ratio: 155.00
• Dividend Yield: N/A
• Price Target: $40.80
• Consensus Rating: Moderate Buy

TG Therapeutics Stock Analysis - MarketRank™

TG Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 343rd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

TG Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 1,150.00%

Earnings Growth

Earnings for TG Therapeutics are expected to grow by 1,150.00% in the coming year, from $0.08 to $1.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TG Therapeutics is 155.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of TG Therapeutics is 155.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.66.

Price to Book Value per Share Ratio

TG Therapeutics has a P/B Ratio of 26.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.71% of the float of TG Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TG Therapeutics has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in TG Therapeutics has recently increased by 0.51%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TG Therapeutics does not currently pay a dividend.

Dividend Growth

TG Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -1.46

Percentage of Shares Shorted

16.71% of the float of TG Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TG Therapeutics has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in TG Therapeutics has recently increased by 0.51%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.88

News Sentiment

TG Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for TG Therapeutics this week, compared to 8 articles on an average week.

Search Interest

Only 6 people have searched for TGTX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

5 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,400.00 in company stock.

Percentage Held by Insiders

10.64% of the stock of TG Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TGTX Stock Analysis - Frequently Asked Questions

How have TGTX shares performed this year?

TG Therapeutics' stock was trading at $30.10 at the beginning of the year. Since then, TGTX shares have increased by 23.6% and is now trading at $37.20.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) posted its earnings results on Wednesday, May, 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by $0.16. The firm's quarterly revenue was up 90.4% on a year-over-year basis.
Read the conference call transcript.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TG Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TGTX
• CIK: 1001316
• Web: www.tgtherapeutics.com
• Phone: (212) 554-4484
• Fax: 212-554-4531
• Employees: 290
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $40.80
• High Stock Price Target: $55.00
• Low Stock Price Target: $22.00
• Potential Upside/Downside: +9.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.24
• Trailing P/E Ratio: 155.00
• Forward P/E Ratio: 465.00
• P/E Growth: N/A
• Net Income: $23.38 million
• Net Margins: 10.13%
• Pretax Margin: 10.80%
• Return on Equity: 18.88%
• Return on Assets: 7.05%

Debt

• Debt-to-Equity Ratio: 1.03
• Current Ratio: 4.02
• Quick Ratio: 3.04

Sales & Book Value

• Annual Sales: $329 million
• Price / Sales: 17.95
• Cash Flow: $0.12 per share
• Price / Cash Flow: 306.10
• Book Value: $1.43 per share
• Price / Book: 26.01

Miscellaneous

• Outstanding Shares: 158,760,000
• Free Float: 141,863,000
• Market Cap: $5.91 billion
• Optionable: Optionable
• Beta: 1.91